ROBERT WOODHAM: Open Payments
NPI 1578621223 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,174 in 158 payments from 15 companies in 2025. Trend: 2023 $2,415 · 2024 $2,484 · 2025 $3,174
Food & beverage: $3,172Education: $2
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 30 | $522 |
| Otsuka America Pharmaceutical, Inc. | 20 | $339 |
| Neurocrine BioSciences, Inc. | 10 | $321 |
| Alkermes, Inc. | 11 | $289 |
| Lundbeck LLC | 12 | $278 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $238 |
| Corium, LLC | 15 | $232 |
| Teva Pharmaceuticals USA, Inc. | 16 | $212 |
| Janssen Pharmaceuticals, Inc | 9 | $198 |
| ABBVIE INC. | 13 | $187 |
Products named: CAPLYTA, REXULTI, INGREZZA, ARISTADA, TRINTELLIX, Azstarys, VRAYLAR, AUSTEDO XR.
Industry payments across TX — which companies pay providers there.
